4//SEC Filing
Dhingra Ankur 4
Accession 0001599298-23-000101
CIK 0001599298other
Filed
Dec 12, 7:00 PM ET
Accepted
Dec 13, 4:49 PM ET
Size
7.0 KB
Accession
0001599298-23-000101
Insider Transaction Report
Form 4
Dhingra Ankur
Chief Financial Officer
Transactions
- Purchase
Common Stock
2023-12-13$2.15/sh+700$1,505→ 235,258 total(indirect: By Trust) - Purchase
Common Stock
2023-12-13$2.17/sh+19,700$42,749→ 254,958 total(indirect: By Trust)
Footnotes (2)
- [F1]The Reporting Person purchased these shares in a single transaction on the open market.
- [F2]The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Documents
Issuer
Summit Therapeutics Inc.
CIK 0001599298
Entity typeother
Related Parties
1- filerCIK 0001849682
Filing Metadata
- Form type
- 4
- Filed
- Dec 12, 7:00 PM ET
- Accepted
- Dec 13, 4:49 PM ET
- Size
- 7.0 KB